MND1: A Protein Implicated in Meiosis and Cancer (G84057)

Target Name: MND1

NCBI ID: G84057

MND1

MND1: A Protein Implicated in Meiosis and Cancer

MND1 (Meiotic Nuclear Division 1) is a protein that plays a crucial role in the process of meiosis, which is a type of cell division that occurs in the germ cells (sperm and egg) to produce gametes. Meiosis is a complex process that involves two rounds of cell division, meiosis I and meiosis II, and MND1 is involved in both stages.

MND1 is a protein that is expressed in the germ cells and is composed of two subunits, alpha and beta. The alpha subunit is approximately 180 amino acids long and has a molecular weight of 19.3 kDa, while the beta subunit is approximately 160 amino acids long and has a molecular weight of 17.9 kDa. Both subunits contain a variety of different domains, including a protein kinase domain, a coiled-coil domain, and a nucleotide-binding domain.

One of the most interesting features of MND1 is its role in meiosis. During meiosis, MND1 is involved in the formation of the nuclear envelope, which is a double layer of phospholipids that surrounds the nucleus. The nuclear envelope helps to ensure that the meiotic chromosomes remain in a compact state and prevent them from coming into contact with each other, which would cause genetic abnormalities.

In addition to its role in meiosis, MND1 has also been shown to play a potential drug target or biomarker. Several studies have suggested that MND1 may be a potential drug target for cancer, particularly germ cell malignancies. This is because MND1 is highly expressed in cancer cells and has been shown to be involved in the development and progression of various types of cancer.

One potential mechanism by which MND1 may be involved in cancer is its role in the regulation of cell cycle progression. As mentioned earlier, MND1 is involved in the formation of the nuclear envelope and helps to ensure that the meiotic chromosomes remain in a compact state. In cancer cells, the ability to properly divide and maintain a stable cell cycle is a key factor in their survival and proliferation. Therefore, MND1 may be a useful biomarker or drug target in the treatment of cancer.

Another potential mechanism by which MND1 may be involved in cancer is its role in the development of resistance to chemotherapy. Many cancer cells are resistant to chemotherapy, which is a common treatment for cancer. This is because these cells have the ability to maintain a stable cell cycle and are able to repair mistakes made by chemotherapy drugs. MND1 may be involved in the regulation of cell cycle progression and DNA repair, which could make it a useful target for cancer chemotherapy.

In addition to its potential role in cancer, MND1 may also be a useful drug target or biomarker in the treatment of other conditions. For example, MND1 has been shown to be involved in the regulation of cell migration and has been suggested as a potential target for the treatment of neurodegenerative diseases. Additionally, MND1 has also been shown to be involved in the regulation of the immune response, which may make it a potential target for the treatment of autoimmune diseases.

Overall, MND1 is a protein that has important roles in the process of meiosis and has been shown to be involved in a variety of cellular processes. Its potential as a drug target or biomarker makes it an attractive target for further research into its role in cancer and other conditions. Further studies are needed to fully understand the role of MND1 in meiosis and its potential as a drug target or biomarker.

Protein Name: Meiotic Nuclear Divisions 1

Functions: Required for proper homologous chromosome pairing and efficient cross-over and intragenic recombination during meiosis (By similarity). Stimulates both DMC1- and RAD51-mediated homologous strand assimilation, which is required for the resolution of meiotic double-strand breaks

The "MND1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MND1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets